# EDGAR Filing Document

**Accession Number:** 0001985493
**File Stem:** 0001213900-26-009803
**Filing Date:** 2026-1
**Character Count:** 7326
**Document Hash:** 7e69f74f5c2fbc79446f4f6ca20b88eb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-009803.hdr.sgml**: 20260129

**ACCESSION NUMBER**: 0001213900-26-009803

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260121

**FILED AS OF DATE**: 20260129

**DATE AS OF CHANGE**: 20260129

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Daewoong Co., Ltd
- **CENTRAL INDEX KEY:** 0001985493

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** M5
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40021
- **FILM NUMBER:** 26580208

**BUSINESS ADDRESS:**
- **STREET 1:** 244, GALMACHI-RO, JUNGWON-GU
- **CITY:** SEONGNAM-SI, GYEONGGI-DO
- **STATE:** M5
- **ZIP:** 13211
- **BUSINESS PHONE:** 82-2-550-8800

**MAIL ADDRESS:**
- **STREET 1:** 244, GALMACHI-RO, JUNGWON-GU
- **CITY:** SEONGNAM-SI, GYEONGGI-DO
- **STATE:** M5
- **ZIP:** 13211
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AEON Biopharma, Inc.
- **CENTRAL INDEX KEY:** 0001837607
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 853940478
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 5 PARK PLAZA
- **STREET 2:** SUITE 1750
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92614
- **BUSINESS PHONE:** (949) 354-6499

**MAIL ADDRESS:**
- **STREET 1:** 5 PARK PLAZA
- **STREET 2:** SUITE 1750
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92614

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Priveterra Acquisition Corp.
- **DATE OF NAME CHANGE:** 20201222

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Daewoong Co., Ltd<br><sub>(Last) (First) (Middle)</sub><br>244, GALMACHI-RO, JUNGWON-GU<br><sub>(Street)</sub><br>SEONGNAM-SI, GYEONGGI-DO, M5 13211<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>AEON Biopharma, Inc. [ AEON ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-01-21 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock, $0.0001 par value per share | 58023 | D |  |
| Common Stock, $0.0001 par value per share | 11951714<sup>(1)(2)(3)</sup> | I | Indirect Beneficial Ownership in the 11,951,714 owned by Daewoong Pharmaceutical Co., Ltd |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Senior Secured Convertible Note | 2026-01-21 | 2030-04-12 | Common Stock |  | <sup>(2)(3)</sup> | I | See footnote<sup>(1)</sup> |
| Pre-Funded Warrants | 2026-01-21 | <sup>(4)</sup> | Common Stock | 11236631 | 0.0001<sup>(2)(3)</sup> | I | See footnote<sup>(1)</sup> |
| Common Stock Warrant | 2026-01-21 | <sup>(5)</sup> | Common Stock | 8000000 | 1.0939<sup>(2)(3)</sup> | I | See footnote<sup>(1)</sup> |

---

### Footnotes:

(1) Daewoong Co., Ltd. ("DWC"), a company organized under the laws of the Republic of Korea, owns 52% of the outstanding shares of Daewoong Pharmaceutical Co., Ltd. ("DWP"), a company organized under the laws of the Republic of Korea; DWC has voting and dispositive power over the securities held by DWP and, therefore, may be deemed to beneficially own such securities indirectly.

(2) As previously disclosed on January 21, 2026, upon completion by AEON Biopharma Inc. (the "Company") of a bona-fide third-party financing for aggregate gross cash proceeds to the Company of at least $30.0 million (a "Qualified Financing"), the convertible notes shall automatically convert into a number of shares of Common Stock or Pre-Funded Warrants equal to: (i) one and three tenths (1.3) multiplied by (ii) the quotient of (a) the principal amount of the convertible notes and all accrued and unpaid interest to be converted divided by (b) the per share price of the common stock sold in the Qualified Financing, and warrants to purchase up to 8,000,000 shares of Common Stock at an exercise price of $1.09392 per share (the "Common Stock Warrant"), resulting in DWP beneficially owning more than 10% of the Issuer's outstanding Common Stock.

(3) (continued from footnote [2]). As a result, DWC beneficially owns an aggregate of (i) 12,009,737 shares of Common Stock (including shares previously held). In addition, DWP received (ii) the New Convertible Note in the principal amount of $1,500,000, (iii) the Pre-Funded Warrants to purchase up to 11,236,631 shares of Common Stock, and (iv) the Common Stock Warrant to purchase up to 8,000,000 shares of Common Stock. DWC may be deemed to beneficially own indirectly the securities described in clauses (ii) through (iv) held by DWP.

(4) The Pre-Funded Warrant is exercisable on or after the Original Issue Date and does not expire until exercised in full.

(5) The Common Stock Warrant is exercisable on or after the Initial Exercise Date and expires at 5:00 p.m. (New York City time) on the Termination Date, as defined in the form of warrant filed as Exhibit 4.2 to the Company's Form 8-K filed with the SEC on November 12, 2025.

**Signature:** Daewoong Co., Ltd., By: /s/ Kyu Sung Lim, Authorized Signatory  
**Date:** 2026-01-23

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**